For adults aged 60 years or older, respiratory syncytial virus (RSV) vaccination is effective for preventing associat ...

Researchers identify signs tied to more severe cases of RSV Date: October 11, 2024 Source: Brigham and Women's Hospital Summary: Clinician-scientists analyzed samples from patients' airways and ...

blistering rashes that usually appear in a specific area of the body and last for 2 to 4 weeks.[8] Respiratory syncytial ...

Oct. 18, 2024 – Older people who aren’t sure about whether to get the vaccine for respiratory syncytial virus (RSV) now have a new set of data to help them make up their minds. A large study ...

RSV is a highly contagious virus affecting the ... it may lead to more serious symptoms like Rapid or labored breathing Bluish skin secondary to shortage of oxygen (cyanosis) Apnea (cessation ...

New vaccines to prevent RSV help address the burden of RSV in older adults and help prevent infection in infants through the vaccination of pregnant individuals. RSV can affect the lower ...

Influenza, RSV and SARS-CoV-2 are still the top three viruses to watch out for in the fall and winter, but several public health tools that have become available in the past year should help boost ...

The Centers for Disease Control and Prevention (CDC) recently warned that respiratory syncytial virus (RSV) and mycoplasma pneumonia, or “walking pneumonia,” are on the rise among very young ...

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. With U.S ...

Three months after revealing that its respiratory syncytial virus (RSV) preventive antibody clesrovimab had passed muster in a phase 2b/3 trial, Merck is putting numbers to the claim. Clesrovimab ...

Notably, quarterly sales of the company’s RSV vaccine, which became a blockbuster after debuting last year, fell by more than 70% year over year, in part due to narrower U.S. recommendations for ...

In years prior to the availability of an RSV vaccine, an estimated 60,000 to 160,000 RSV-associated hospitalizations and 6,000 to 10,000 RSV-associated deaths occurred annually among U.S. adults ...